VectivBio

Transforming Lives

Investors & Media

VectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.

Latest Presentation

Recent News and Upcoming Events

PRESS RELEASES

Nov 10, 2021

VectivBio Announces Third Quarter 2021 Business Update

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)- -IND

Read More View All

EVENTS & PRESENTATIONS

Nov 11, 2021 at 9:40 AM EST

Credit Suisse 30th Annual Healthcare Conference

Click here for webcast

Read More View All

Stock Performance Summary

Change
Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.